1.
Hird AE, Magee DE, Cheung DC, Matta R, Kulkarni GS, Nam RK. Abiraterone vs. docetaxel for metastatic hormone-sensitive prostate cancer: A microsimulation model. CUAJ [Internet]. 2020 Mar. 29 [cited 2024 Mar. 29];14(9):E418-27. Available from: https://cuaj.ca/index.php/journal/article/view/6234